Which has higher earnings & valuation, GERN or PYXS?

Pyxis Oncology has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 5.28 -$83.50M -$0.11 N/A Pyxis Oncology $11.04M 24.41 -$79.62M -$1.41 N/A

Is GERN or PYXS more profitable?

Pyxis Oncology has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Geron -34.17% -24.48% -10.30% Pyxis Oncology N/A -215.23% -112.19%

Is DSGN or PYXS more profitable?

Design Therapeutics' return on equity of -34.03% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -34.03% -32.05% Pyxis Oncology N/A -215.23% -112.19%

Is ANNX or PYXS more profitable?

Annexon's return on equity of -106.15% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Pyxis Oncology N/A -215.23% -112.19%

Is PYXS or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -48.26% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Olema Pharmaceuticals N/A -48.26% -43.04%

Pyxis Oncology (PYXS) Competitors

$3.23 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

PYXS vs. GERN, DSGN, ANNX, OLMA, and DBVT

Should you buy Pyxis Oncology stock or one of its competitors? Pyxis Oncology's main competitors and comparable companies include Geron (GERN), Design Therapeutics (DSGN), Annexon (ANNX), Olema Pharmaceuticals (OLMA), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pyxis Oncology compare to Geron?

Geron (NASDAQ:GERN) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Geron has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Pyxis Oncology has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Pyxis Oncology	N/A	-215.23%	-112.19%

Geron presently has a consensus target price of $4.00, indicating a potential upside of 164.90%. Pyxis Oncology has a consensus target price of $7.50, indicating a potential upside of 132.20%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Pyxis Oncology has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.28	-$83.50M	-$0.11	N/A
Pyxis Oncology	$11.04M	24.41	-$79.62M	-$1.41	N/A

73.7% of Geron shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Geron had 4 more articles in the media than Pyxis Oncology. MarketBeat recorded 5 mentions for Geron and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat Geron's score of 1.76 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Geron	Very Positive
Pyxis Oncology	Very Positive

Summary

Pyxis Oncology beats Geron on 9 of the 16 factors compared between the two stocks.

How does Pyxis Oncology compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Design Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 9.20%. Pyxis Oncology has a consensus price target of $7.50, indicating a potential upside of 132.20%. Given Pyxis Oncology's higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Design Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Design Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Pyxis Oncology	$11.04M	24.41	-$79.62M	-$1.41	N/A

Design Therapeutics' return on equity of -34.03% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Pyxis Oncology	N/A	-215.23%	-112.19%

In the previous week, Design Therapeutics had 6 more articles in the media than Pyxis Oncology. MarketBeat recorded 7 mentions for Design Therapeutics and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat Design Therapeutics' score of 1.66 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Design Therapeutics	Very Positive
Pyxis Oncology	Very Positive

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Design Therapeutics beats Pyxis Oncology on 10 of the 15 factors compared between the two stocks.

How does Pyxis Oncology compare to Annexon?

Annexon (NASDAQ:ANNX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Annexon's return on equity of -106.15% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Pyxis Oncology	N/A	-215.23%	-112.19%

Annexon currently has a consensus target price of $15.33, suggesting a potential upside of 208.52%. Pyxis Oncology has a consensus target price of $7.50, suggesting a potential upside of 132.20%. Given Annexon's higher possible upside, research analysts clearly believe Annexon is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

39.1% of Pyxis Oncology shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annexon has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Pyxis Oncology has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Pyxis Oncology	$11.04M	24.41	-$79.62M	-$1.41	N/A

In the previous week, Annexon had 5 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for Annexon and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat Annexon's score of 1.33 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Annexon	Positive
Pyxis Oncology	Very Positive

Summary

Pyxis Oncology beats Annexon on 8 of the 14 factors compared between the two stocks.

How does Pyxis Oncology compare to Olema Pharmaceuticals?

Pyxis Oncology (NASDAQ:PYXS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Olema Pharmaceuticals' return on equity of -48.26% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Pyxis Oncology has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 5 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat Olema Pharmaceuticals' score of 1.41 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Very Positive
Olema Pharmaceuticals	Positive

Pyxis Oncology has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04M	24.41	-$79.62M	-$1.41	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Pyxis Oncology currently has a consensus target price of $7.50, indicating a potential upside of 132.20%. Olema Pharmaceuticals has a consensus target price of $42.40, indicating a potential upside of 312.85%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Olema Pharmaceuticals beats Pyxis Oncology on 9 of the 14 factors compared between the two stocks.

How does Pyxis Oncology compare to DBV Technologies?

Pyxis Oncology (NASDAQ:PYXS) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pyxis Oncology has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04M	24.41	-$79.62M	-$1.41	N/A
DBV Technologies	$5.64M	150.96	-$146.95M	-$3.51	N/A

Pyxis Oncology has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.93, suggesting that its stock price is 193% less volatile than the broader market.

Pyxis Oncology has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Pyxis Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 132.20%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 258.20%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, DBV Technologies had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat DBV Technologies' score of 1.34 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Very Positive
DBV Technologies	Positive

Summary

Pyxis Oncology beats DBV Technologies on 9 of the 17 factors compared between the two stocks.

Get Pyxis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYXS vs. The Competition

Export

Metric	Pyxis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$269.41M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-2.29	11.62	273.16	25.42
Price / Sales	24.41	1,380.91	631.89	104.53
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	3.76	16.92	11.08	6.36
Net Income	-$79.62M	-$22.74M	$3.48B	$349.79M
7 Day Performance	4.87%	-0.31%	0.13%	-0.80%
1 Month Performance	12.54%	9.80%	7.08%	4.13%
1 Year Performance	152.34%	55.66%	24.67%	15.17%

Pyxis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYXS Pyxis Oncology	3.2705 of 5 stars	$3.23 flat	$7.50 +132.2%	+152.3%	$269.41M	$11.04M	N/A	60	Positive News Gap Up
GERN Geron	2.2272 of 5 stars	$1.55 +1.6%	$4.00 +158.9%	+7.9%	$992.62M	$204.56M	N/A	70
DSGN Design Therapeutics	1.3257 of 5 stars	$15.70 +3.1%	$16.50 +5.1%	+173.2%	$982.82M	N/A	N/A	40
ANNX Annexon	2.3155 of 5 stars	$5.18 +2.3%	$15.33 +196.3%	+141.3%	$981.08M	N/A	N/A	60	Positive News
OLMA Olema Pharmaceuticals	2.6967 of 5 stars	$10.96 +5.0%	$42.40 +287.0%	+88.1%	$958.56M	N/A	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYXS) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pyxis Oncology (PYXS) Competitors

PYXS vs. GERN, DSGN, ANNX, OLMA, and DBVT

How does Pyxis Oncology compare to Geron?

Summary

How does Pyxis Oncology compare to Design Therapeutics?

Summary

How does Pyxis Oncology compare to Annexon?

Summary

How does Pyxis Oncology compare to Olema Pharmaceuticals?

Summary

How does Pyxis Oncology compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pyxis Oncology (PYXS) Competitors

PYXS vs. GERN, DSGN, ANNX, OLMA, and DBVT

How does Pyxis Oncology compare to Geron?

Which has more risk and volatility, GERN or PYXS?

Is GERN or PYXS more profitable?

Do analysts recommend GERN or PYXS?

Which has higher earnings & valuation, GERN or PYXS?

Do insiders & institutionals have more ownership in GERN or PYXS?

Does the media refer more to GERN or PYXS?

Summary

How does Pyxis Oncology compare to Design Therapeutics?

Do analysts recommend DSGN or PYXS?

Which has more volatility and risk, DSGN or PYXS?

Which has preferable valuation & earnings, DSGN or PYXS?

Is DSGN or PYXS more profitable?

Does the media refer more to DSGN or PYXS?

Do insiders and institutionals have more ownership in DSGN or PYXS?

Summary

How does Pyxis Oncology compare to Annexon?

Is ANNX or PYXS more profitable?

Do analysts recommend ANNX or PYXS?

Do institutionals & insiders hold more shares of ANNX or PYXS?

Which has more risk & volatility, ANNX or PYXS?

Which has higher valuation and earnings, ANNX or PYXS?

Does the media favor ANNX or PYXS?

Summary

How does Pyxis Oncology compare to Olema Pharmaceuticals?

Do institutionals and insiders have more ownership in PYXS or OLMA?

Is PYXS or OLMA more profitable?

Which has more risk and volatility, PYXS or OLMA?

Does the media prefer PYXS or OLMA?

Which has better valuation and earnings, PYXS or OLMA?

Do analysts recommend PYXS or OLMA?

Summary

How does Pyxis Oncology compare to DBV Technologies?

Do institutionals & insiders hold more shares of PYXS or DBVT?

Which has preferable earnings & valuation, PYXS or DBVT?

Which has more volatility and risk, PYXS or DBVT?

Is PYXS or DBVT more profitable?

Do analysts prefer PYXS or DBVT?

Does the media prefer PYXS or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools